US$ 29.92
contraindications for glp 1 agonists Independent Nurse - GLP-1 and GIP/GLP-1 receptor type 2 diabetes Glucagon-like peptide-1 receptor agonists in
Description
2013;5 doi: 10.1126/scitranslmed.3007218

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: From randomised trials to clinical practice

This therapeutic area is a powerful example of how scientific innovation, strong clinical evidence, and strategic market positioning can create an entirely new blockbuster segment

The key is comparing actual evidence, not just marketing promises

We find that those who have current or past experience with GLP-1 drugs expect the drugs to have a bigger impact on consumers preferences and habits

Aten Primaria (2017) 49:2949